Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma.

H. M. Schuller, H. K. Plummer, P. N. Bochsler, P. Dudric, John Bell, R. E. Harris

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Pulmonary adenocarcinoma (PAC) is the leading type of lung cancer and is highly resistant to conventional cancer therapy. A better understanding of the regulatory mechanisms which control the growth of this deadly malignancy are urgently needed to develop more effective cancer intervention strategies. Recent studies have shown that PAC frequently overexpresses cyclooxygenase-2 (COX-2). This enzyme converts arachidonic acid (AA) into several metabolites, some of which have been identified as modulators of mitogenesis and apoptosis. Accordingly, the AA cascade and COX-2 are currently widely studied as potential targets for lung cancer prevention. Recent studies by our research group have shown that cell lines derived from human PACs express beta1- and beta2-adrenergic receptors, which regulate the release of AA and DNA synthesis. Moreover, we have demonstrated that an antagonist for beta-adrenergic receptors or aspirin inhibited the development of experimentally induced PAC in a hamster model. These findings suggest that beta-adrenergic receptors may serve as upstream regulators of AA and COX-2-mediated PAC growth. However, no information is currently available on the expression of beta-adrenergic receptors and its possible correlation with the expression of COX-2 in tissue samples from human PAC, casting some doubt on the significance of these findings in vitro and in an animal model. In the current study, we have therefore analyzed tissue samples of human PACs for the expression of beta1-and beta2-adrenergic receptors as well as COX-2 by reverse transcription polymerase chain reaction (RT-PCR) or immunohistochemistry. Our data show that seven out of eight samples co-expressed COX-2 and one or both of these beta-adrenergic receptors, supporting the experimental evidence for a functional link between these neurotransmitter receptors and the AA cascade in the regulation of human PAC.

Original languageEnglish (US)
Pages (from-to)445-449
Number of pages5
JournalInternational Journal of Oncology
Volume19
Issue number3
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Receptors, Adrenergic, beta
Cyclooxygenase 2
Arachidonic Acid
Prostaglandin-Endoperoxide Synthases
Adrenergic Receptors
Lung Neoplasms
Neoplasms
Neurotransmitter Receptor
Growth
Cricetinae
Aspirin
Reverse Transcription
Adenocarcinoma of lung
Animal Models
Immunohistochemistry
Apoptosis
Cell Line
Polymerase Chain Reaction
DNA
Enzymes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Schuller, H. M., Plummer, H. K., Bochsler, P. N., Dudric, P., Bell, J., & Harris, R. E. (2001). Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma. International Journal of Oncology, 19(3), 445-449.

Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma. / Schuller, H. M.; Plummer, H. K.; Bochsler, P. N.; Dudric, P.; Bell, John; Harris, R. E.

In: International Journal of Oncology, Vol. 19, No. 3, 01.01.2001, p. 445-449.

Research output: Contribution to journalArticle

Schuller, HM, Plummer, HK, Bochsler, PN, Dudric, P, Bell, J & Harris, RE 2001, 'Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma.', International Journal of Oncology, vol. 19, no. 3, pp. 445-449.
Schuller, H. M. ; Plummer, H. K. ; Bochsler, P. N. ; Dudric, P. ; Bell, John ; Harris, R. E. / Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma. In: International Journal of Oncology. 2001 ; Vol. 19, No. 3. pp. 445-449.
@article{735c82441ad344a9be63e4ebef8e2fbf,
title = "Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma.",
abstract = "Pulmonary adenocarcinoma (PAC) is the leading type of lung cancer and is highly resistant to conventional cancer therapy. A better understanding of the regulatory mechanisms which control the growth of this deadly malignancy are urgently needed to develop more effective cancer intervention strategies. Recent studies have shown that PAC frequently overexpresses cyclooxygenase-2 (COX-2). This enzyme converts arachidonic acid (AA) into several metabolites, some of which have been identified as modulators of mitogenesis and apoptosis. Accordingly, the AA cascade and COX-2 are currently widely studied as potential targets for lung cancer prevention. Recent studies by our research group have shown that cell lines derived from human PACs express beta1- and beta2-adrenergic receptors, which regulate the release of AA and DNA synthesis. Moreover, we have demonstrated that an antagonist for beta-adrenergic receptors or aspirin inhibited the development of experimentally induced PAC in a hamster model. These findings suggest that beta-adrenergic receptors may serve as upstream regulators of AA and COX-2-mediated PAC growth. However, no information is currently available on the expression of beta-adrenergic receptors and its possible correlation with the expression of COX-2 in tissue samples from human PAC, casting some doubt on the significance of these findings in vitro and in an animal model. In the current study, we have therefore analyzed tissue samples of human PACs for the expression of beta1-and beta2-adrenergic receptors as well as COX-2 by reverse transcription polymerase chain reaction (RT-PCR) or immunohistochemistry. Our data show that seven out of eight samples co-expressed COX-2 and one or both of these beta-adrenergic receptors, supporting the experimental evidence for a functional link between these neurotransmitter receptors and the AA cascade in the regulation of human PAC.",
author = "Schuller, {H. M.} and Plummer, {H. K.} and Bochsler, {P. N.} and P. Dudric and John Bell and Harris, {R. E.}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "19",
pages = "445--449",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Co-expression of beta-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma.

AU - Schuller, H. M.

AU - Plummer, H. K.

AU - Bochsler, P. N.

AU - Dudric, P.

AU - Bell, John

AU - Harris, R. E.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Pulmonary adenocarcinoma (PAC) is the leading type of lung cancer and is highly resistant to conventional cancer therapy. A better understanding of the regulatory mechanisms which control the growth of this deadly malignancy are urgently needed to develop more effective cancer intervention strategies. Recent studies have shown that PAC frequently overexpresses cyclooxygenase-2 (COX-2). This enzyme converts arachidonic acid (AA) into several metabolites, some of which have been identified as modulators of mitogenesis and apoptosis. Accordingly, the AA cascade and COX-2 are currently widely studied as potential targets for lung cancer prevention. Recent studies by our research group have shown that cell lines derived from human PACs express beta1- and beta2-adrenergic receptors, which regulate the release of AA and DNA synthesis. Moreover, we have demonstrated that an antagonist for beta-adrenergic receptors or aspirin inhibited the development of experimentally induced PAC in a hamster model. These findings suggest that beta-adrenergic receptors may serve as upstream regulators of AA and COX-2-mediated PAC growth. However, no information is currently available on the expression of beta-adrenergic receptors and its possible correlation with the expression of COX-2 in tissue samples from human PAC, casting some doubt on the significance of these findings in vitro and in an animal model. In the current study, we have therefore analyzed tissue samples of human PACs for the expression of beta1-and beta2-adrenergic receptors as well as COX-2 by reverse transcription polymerase chain reaction (RT-PCR) or immunohistochemistry. Our data show that seven out of eight samples co-expressed COX-2 and one or both of these beta-adrenergic receptors, supporting the experimental evidence for a functional link between these neurotransmitter receptors and the AA cascade in the regulation of human PAC.

AB - Pulmonary adenocarcinoma (PAC) is the leading type of lung cancer and is highly resistant to conventional cancer therapy. A better understanding of the regulatory mechanisms which control the growth of this deadly malignancy are urgently needed to develop more effective cancer intervention strategies. Recent studies have shown that PAC frequently overexpresses cyclooxygenase-2 (COX-2). This enzyme converts arachidonic acid (AA) into several metabolites, some of which have been identified as modulators of mitogenesis and apoptosis. Accordingly, the AA cascade and COX-2 are currently widely studied as potential targets for lung cancer prevention. Recent studies by our research group have shown that cell lines derived from human PACs express beta1- and beta2-adrenergic receptors, which regulate the release of AA and DNA synthesis. Moreover, we have demonstrated that an antagonist for beta-adrenergic receptors or aspirin inhibited the development of experimentally induced PAC in a hamster model. These findings suggest that beta-adrenergic receptors may serve as upstream regulators of AA and COX-2-mediated PAC growth. However, no information is currently available on the expression of beta-adrenergic receptors and its possible correlation with the expression of COX-2 in tissue samples from human PAC, casting some doubt on the significance of these findings in vitro and in an animal model. In the current study, we have therefore analyzed tissue samples of human PACs for the expression of beta1-and beta2-adrenergic receptors as well as COX-2 by reverse transcription polymerase chain reaction (RT-PCR) or immunohistochemistry. Our data show that seven out of eight samples co-expressed COX-2 and one or both of these beta-adrenergic receptors, supporting the experimental evidence for a functional link between these neurotransmitter receptors and the AA cascade in the regulation of human PAC.

UR - http://www.scopus.com/inward/record.url?scp=0035458441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035458441&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 445

EP - 449

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -